The dynamic balance between histone acetylation and deacetylation plays a significant role in the regulation of gene transcription. Much of our current understanding of this transcriptional control comes from the use of HDAC inhibitors such as trapoxin A (TPX), which leads to hyperacetylated histone, alters local chromatin architecture and transcription and results in tumor cell death. In this study, we treated tumor cells with TPX and HDAC1 antisense oligonucleotides, and analysed the transcriptional consequences of HDAC inhibition. Among other genes, the small GTPase RhoB was found to be significantly upregulated by TPX and repressed by HDAC1. The induction of RhoB by HDAC inhibition was mediated by an inverted CCAAT box in the RhoB promoter. Interestingly, measurement of RhoB transcription in B130 tumor-derived cell lines revealed low expression in almost all of these samples, in contrast to RhoA and RhoC. Accumulating evidence indicates that the small GTPase Rho proteins are involved in a variety of important processes in cancer, including cell transformation, survival, invasion, metastasis and angiogenesis. This study for the first time demonstrates a link between HDAC inhibition and RhoB expression and provides an important insight into the mechanisms of HDACmediated transcriptional control and the potential therapeutic benefit of HDAC inhibition.
Introduction
The eukaryotic genome is compacted into nucleosomes to form chromatin and dynamic alterations in chromatin structure can facilitate or suppress access of transcription factors to DNA, leading to transcription regulation. Changes in the acetylation of nucleosomal core histones play a pivotal role in this regulation.
Typically, increased levels of histone acetylation are associated with active transcription, whereas decreased acetylation is associated with transcription repression (Grunstein, 1997; Strahl and Allis, 2000) .
The acetylation status of histones is dynamically controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs) . A large number of HATs have been identified as transcriptional coactivators, among them GCN5 (general control nonderepressible), (CBP)/p300 (cAMP response element binding protein-binding protein), PCAF (p300/CBP-associated factor), SRC-1 (steroid receptor coactivator) and TAF250 (TATA box binding protein associated factor) (Chen et al., 2001a; Nakatani, 2001) . A total of 18 mammalian HDACs described to date are found to be associated with transcription repression and have been classified into three classes (Imai et al., 2000; Gray and Ekstrom, 2001; Khochbin et al., 2001) . Class I, encompassing HDAC1-3, 8 and 11 are related to Rpd3 (a first class of yeast histone deacetylase). Class II, including HDAC4-7, 9 and 10 are related to Hda1 (a second class of yeast histone deacetylase) (Bertos et al., 2001; Zhou et al., 2001) . Finally, Class III, also known as the Sir2 (silent information regulator 2) family, consists of seven genes related to yeast Sir2, and possess nicotinamide-adenine dinucleotide (NAD þ )-dependent deacetylase activity (Vaziri et al., 2001) .
HDACs are usually found in large multiprotein complexes that regulate gene transcription. A number of transcriptional repressors and corepressors, such as Sin3, SMRT (silencing mediator of retinoid acid and thyroid hormone receptor) and N-CoR (nuclear receptor corepressor), have been shown to recruit HDAC containing complexes to promoter regions (Imai et al., 2000; Gray and Ekstrom, 2001; Khochbin et al., 2001) . Evidence is accumulating that HDACs differ in cellular localization and presence in transcription complexes regulating a variety of genes, suggesting that different HDACs may have different biological activities (Jones et al., 2001) . In addition to deacetylation of histones, HDACs have been shown to regulate gene expression by deacetylating transcription factors, such as p53, the erythroid kruppel-like factor (EKLF) and the erythroid cell differentiation factor GATA-1 (Pazin and Kadonaga, 1997; Liu et al., 1999) .
HDAC inhibitors are potent inducer of growth arrest, differentiation and apoptotic cell death in a variety of transformed cells in culture and in tumor-bearing animals (Weidle and Grossmann, 2000; Marks et al., 2001) . Hence, HDAC inhibitors are being evaluated as potent anticancer agents. Trapoxin A (TPX) is a potent, noncompetitive HDAC inhibitor, which has been used to explore the mechanisms by which histone deacetylation alters transcription (Furumai et al., 2001) . The action of HDAC inhibitors on gene expression appears to be selective, altering the transcription of only a limited number of genes in cultured tumor cells (Van Lint et al., 1996) . The basis for this gene selectivity of HDAC inhibitors is unknown.
The biochemical events subsequent to HDAC inhibition that lead to cell cycle arrest, cellular differentiation and apoptosis have not yet been identified. We have used a genomic approach to identify the transcriptional consequences of HDAC inhibition and to elucidate molecular mechanisms of HDAC-mediated transcriptional repression. Previously, we and others found that the expression of p21
Waf1 was induced following inhibition of HDAC by TPX (Van Lint et al., 1996; Sambucetti et al., 1999) . In addition, TGF-b type II receptor gene (TbRII) (Park et al., 2002) , multidrug resistance gene 1 (MDR1) (Jin and Scotto, 1998 ) and thioredoxin binding protein-2 (TBP-2) (Butler et al., 2002) were also found to be upregulated following treatment of tumor cells with HDAC inhibitor. In this study, we used DNA microarrays to identify additional genes that were modified by HDAC inhibition and found that RhoB was one of the most significantly upregulated gene in H1299 cells. It has been shown that the small GTPase Rho proteins are involved in a variety of tumorigenic processes, including cell transformation, survival, invasion, metastasis and angiogenesis (Chen et al., 2000; Prendergast, 2001; Adnane et al., 2002; Sahai and Marshall, 2002) . The altered expression or activity of Rho proteins might be crucial to cancer progression and therapeutic responses. Hence, we focus our investigation on revealing the molecular mechanism of RhoB induction by HDAC inhibition.
Rho proteins have been reported to possess diverse cellular functions, including regulation of cytoskeletal actin organization, adhesion, motility, vesicle transport, cell-cycle progression, cytokinesis and transcription (Prendergast, 2001) . RhoB belongs to the Rho subgroup of the Ras superfamily, and shares over 85% homology with RhoA and RhoC, two other members of the Rho subgroup. However, each protein plays a distinct cellular biological role (Prendergast, 2001; Takai et al., 2001; Sahai and Marshall, 2002) . There are several features that distinguish RhoB from other Rho proteins. RhoB is an immediate early response gene that is rapidly induced by various growth and stress stimuli, especially DNA-damage reagents (Jahner and Hunter, 1991; Fritz et al., 1995; Engel et al., 1998) and is turned over much more rapidly than other Rho proteins. It was also shown that RhoB has an important role in growth inhibition and apoptosis in transformed cells (Chen et al., 2000; Liu, 2001; Adnane et al., 2002) .
In this study, for the first time a molecular mechanism of RhoB induction by HDAC inhibition was deciphered. The suppression of RhoB transcription by HDAC was found to be mediated by an inverted CCAAT element in its promoter. Furthermore, microarray analysis of RhoB gene expression in transformed cells demonstrates almost consistently low expression, strongly suggesting that low levels of RhoB expression might be involved in high proliferation. These results support the model that RhoB has a growth inhibitory function and may be a negative modifier in cancer.
Results

RhoB expression is induced following HDAC inhibition
To identify transcriptional events that occur as a result of HDAC inhibition, we used DNA microarray analysis to monitor gene expression in response to HDAC inhibition by TPX treatment. By comparing changes in TPX-treated versus untreated human nonsmall lung carcinoma, H1299 cells, a gene expression pattern that correlated with HDACs inhibition was determined. Among several genes, the small GTPase RhoB was found to be one of the most significantly upregulated genes, about eightfold, in response to TPX treatment in these cells (Figure 1a ). p21 waf1 , a gene previously reported to be induced in response to HDAC inhibition (Sambucetti et al., 1999) was found to be upregulated by about sixfold. Interestingly, the expression of two other Rho GTPase subfamily members, RhoA and RhoC, which share over 85% homology with RhoB, was unchanged following the TPX treatment. We performed Northern and Western blots to analyse RhoB, providing independent validation, as well as extending the results of the DNA microarray experiments (Figure 1b, 1c) . Increased levels of RhoB protein could be detected as early as 6 h, with maximum levels observed by 24-48 h after TPX treatment ( Figure 1c ).
RhoB is differentially expressed in transformed cell lines
The use of HDAC inhibitors in the clinic as new cancer therapeutics and the induction of RhoB in response to an HDAC inhibitor promoted us to survey the status of RhoB expression in tumor cell lines. We used DNA microarray analysis to characterize RhoB, RhoA and RhoC expression in 136 cell lines. RhoB levels were low in most transformed cell lines, compared with the expression levels of RhoA and RhoC. Moreover, RhoB expression levels were lower in transformed cells than in corresponding normal cells (Figure 2 ). In addition, low RhoB expression was also detected in several tumor tissues relative to corresponding normal tissues (data not shown).
Human and mouse RhoB promoters
To understand the induction of RhoB following TPXmediated inhibition of HDACs, and to determine whether this induction could be mapped to the RhoB promoter, we cloned the region of the human RhoB gene from À1224 to À253 (relative to the translation initiation site, þ 1 ATG) upstream of a luciferase reporter gene (Figure 3a ). On the basis of EST and transcript data analysis, a transcriptional initiation site was predicted at position À428 (G). Comparison of the (Fritz and Kaina, 1997) revealed that the two promoters are highly conserved around the potential transcription initiation site. Furthermore, these promoters also share many putative transcription factors binding sites ( Figure 3b ).
An inverted CCAAT box in the RhoB promoter is crucial for RhoB induction
The effect of TPX on the transcriptional activity of the RhoB promoter was determined in H1299 cells transfected with RhoB promoter-reporter constructs. Luciferase activity driven by the RhoB promoter was induced to about 8-10-fold following TPX treatment ( Figure 3c ). To define the region required for transcriptional induction, we transfected a series of RhoB promoter 5 0 deletion constructs into H1299 cells. All these constructs generated were induced similarly as shown by luciferase activity (Figure 3c) .
Examination of the RhoB promoter sequences that were encompassed in the shorter RhoB promoter luciferase construct (À497 and À392) and were also induced by TPX, revealed the presence of two potential transcription factor binding sites. A putative TATA box 0 ) at position À451 with a five nucleotide space between these two DNA elements (Figure 3a) . To define which, if any, of these elements were required for TPX induction, we examined the activation of luciferase constructs containing point mutations in the CCAAT and TATA boxes, as well as a construct containing an insertion of three nucleotides that changed the distance between these two boxes. The response of RhoB promoter to TPX was significantly reduced when the inverted CCAAT box (5 0 -ATTGG-3 0 ) was mutated to 5 0 -TTTAG-3 0 . However, mutation of the TATA box (5 0 -TATATTAA-3 0 ) to 5 0 -CAGATCAA-3 0 had no significant effect on RhoB promoter induction. In addition, the insertion of three nucleotides (AAA) between the CCAAT and TATA boxes had no effect. These data indicated that the inverted CCAAT box is critical for the induction of the RhoB promoter following TPXmediated inhibition of HDACs (Figure 3d ).
Nuclear protein specifically binds to the inverted CCAAT element in the RhoB promoter
To ensure that nuclear proteins bind to the inverted CCAAT element, which mediated RhoB promoter activity in response to TPX treatment, gel shift assays were performed. Nuclear extracts were prepared from TPX-treated or untreated H1299 cells, and RhoB promoter sequence from À497 to À392 was used as probe. As shown in Figure 4 , DNA/protein complex was observed. Moreover, the complex was only competed by excess unlabeled probes containing the wild-type CCAAT element, but not by excess unlabeled oligonucleotides containing the mutant CCAAT element. TPX Elevated levels of acetylated histone H3 and H4 in TPX responsive region of RhoB promoter by TPX treatment
To investigate whether RhoB promoter transcriptional activation correlated with acetylation of Histone H3 or H4, chromatin immunoprecipitations were performed with TPX-treated and untreated H1299 cells using antibodies against acetylated histone H3 or H4. The immunoprecipitated DNAs were analysed by PCR using RhoB-specific primers. As shown in Figure 5 , TPX treatment for 12 or 24 h increased histone H3 and H4 acetylation associated with RhoB promoter region from À557 to À412, which encompassed TPX-responsive sequences. Interestingly, TPX did not effect the acetylation level of RhoB promoter region between À823 and À536 located upstream of the TPX-responsive sequences.
The RhoB promoter is associated with and repressed by HDAC1
To determine whether the induction of the RhoB promoter by TPX is related to in vivo recruitment of HDAC complexes to the promoter, we investigated the association of HDACs with the RhoB promoter by chromatin immunoprecipition assay. H1299 cells were fixed in 1% formaldehyde, and chromatin lysates were immunoprecipited with specific antibodies against HDAC1, 2 and 6. RhoB promoter fragment from À557 to À412 was found to be associated with HDAC1 and HDAC2, but not with HDAC6. As a control, chromatin was immunoprecipitated in the absence of specific antibodies and the same RhoB promoter fragment was not detected (Figure 6a ). As shown in Figure 3 , the change in the induction of luciferase activity following TPX treatment was mediated mainly by the inverted CCAAT box in the RhoB promoter. To investigate the direct effect of HDACs on the RhoB promoter, the effects of ectopic expression of HDAC1 and HDAC6 on RhoB promoter constructs were tested. The activity of RhoB promoter was repressed with overexpression of HDAC1, but not Figure 5 Inhibition of HDAC by TPX leads to increased histone H3 and H4 acetylation in the TPX responsive region of RhoB promoter. CHIP assays were performed using chromatin isolated from H1299 cells either treated with TPX for 12 or 24 h or 0.1% DMSO. Antibodies aganist acetylated histones H3 and H4 were used to isolate acetylated chromatin. PCR primers for two regions, one of them encompassing the TPX-responsive region, were used to amplify the RhoB promoter fragments. Input: input DNAs were used to show the relative locations of the PCR products. M: DNA 1 kb ladder. þ 1: translation start site (Figure 6b ). However, HDAC1 overexpression had no effect on the construct containing the mutation in the inverted CCAAT box. These results demonstrated that RhoB promoter activity is specifically regulated by HDAC1, but not by HDAC6 via the inverted CCAAT box (Figure 6b ).
Expression of RhoB is induced by blocking HDAC1 synthesis
To determine the effect of specific HDAC1 blockade on RhoB expression, we used antisense oligonucleotides designed against the HDAC1 sequence. Anti-HDAC antisense oligonucleotides, as well as mismatch oligonucleotide as controls, were synthesized and transfected into H1299 cells. One antisense oligonucleotide in particular, NAS 6887, was found to significantly inhibit HDAC1 mRNA levels, and was subsequently used in the experiment. Samples from NAS 6887-treated and mismatch (NAS 7618)-treated cells were analysed by real time RT-PCR and by Western blot for HDAC1 and RhoB expression levels. The expression of HDAC1 was blocked by NAS 6887, and RhoB protein level was significantly induced. In contrast, no effects on RhoB expression were found in cells transfected with the NAS 7618 (mismatch) and NAS 5596 (unrelated luciferase) oligonucleotides (Figure 7 ).
Discussion
HDAC inhibitors have shown considerable potential as new antitumor agents due to their ability to induce differentiation and apoptosis via transcriptional modulation. Several HDAC inhibitors are presently being evaluated in clinical trials . To elucidate the biological consequences of HDAC inhibition, we determined the global gene expression profiles of H1299 cells following inhibition of HDAC with TPX. Among other genes, the small GTPase RhoB was one of the most significantly upregulated in response to TPX. The increased levels of RhoB mRNA, protein and promoter activity suggested that the RhoB gene was transcriptionally regulated by HDACs, thus linking RhoB expression and HDAC inhibition. In contrast, the transcription of two other closely related Rho GTPase subfamily members, RhoA and RhoC, was not altered in response to TPX-mediated HDAC inhibition. Chromatin IP experiments indicated that HDAC1 and HDAC2, but not HDAC6, were associated with the RhoB promoter and consistent with this observation, overexpression of HDAC1 could specifically repress the RhoB promoter, whereas HDAC6 had no effect on RhoB expression. In addition, antisense inhibition of HDAC1 induced RhoB gene expression, providing independent evidence that HDAC1 mediates RhoB transcriptional repression. We investigated the specific mechanism of transcriptional regulation of RhoB by HDAC through determining the effect of TPX inhibition on a series of RhoB promoter deletions. Interestingly, induction of expression of all these deletions was similar following TPX treatment. To define the TPX responsive sequences, mutations were introduced into the CCAAT and the TATA boxes in the proximal region of the RhoB promoter. Only promoter constructs harboring mutations in the inverted CCAAT box lost the ability to be induced following TPX treatment, indicating the involvement of this sequence in the repression of RhoB promoter activity by HDAC. Furthermore, mutation in this CCAAT box reduced the ability of HDAC1 to induce repression of RhoB promoter activity. In addition, chromatin immunoprecipitation assays revealed that TPX increased the level of chromatin acetylation in the TPX-responsive region of the RhoB promoter containing the inverted CCAAT box. Gel shift assays indicated that NF-Y complex bind to this inverted CCAAT box in RhoB promoter in vitro (data not shown), suggesting that NF-Y might be a component in the HDAC1/CCAAT complex.
These findings represent the first evidence that HDAC activity is involved in the transcriptional regulation of RhoB by a specific element in its promoter.
It has been reported that the RhoB promoter can also be induced by a variety of growth and stress stimuli (Jahner and Hunter, 1991; Fritz et al., 1995; Engel et al., 1998) and studies have shown that the CCAAT box in the RhoB promoter is involved in transcription activation by genotoxicants Kaina, 1997, 2001b) . Previously, p21 waf1 was reported also to be induced by TPX, and an SP1 site in its promoter was shown to mediate this response (Sambucetti et al., 1999) . Interestingly, the Sp1 site in the RhoB promoter was not found to mediate the effect of HDAC inhibition. Thus, supporting a model of at least two classes of genes regulated by HDAC inhibition, genes that required Sp1 sites and genes that required CCAAT sites as suggested recently by Richon's group (Butler et al., 2002) .
Recent findings indicated that altered expression or activity of Rho proteins might be crucial to cancer progression and therapeutic responses (Prendergast, 2001 ; Adnane et al., 2002; Sahai and Marshall, 2002) .
As an important step toward understanding RhoB function, and the findings that RhoB induction is mediated by HDAC inhibition, we performed a survey of RhoB expression in transformed cells. Significantly low levels of RhoB expression were observed in most of the cells, suggesting that RhoB suppression is associated with high proliferation rates. The activity of Rho family members has been reported to be determined by GTP/ GDP binding (Prendergast, 2001; Takai et al., 2001 ) and post-translation modifications (isoprenylation) (Liu and Prendergast, 2000) . However, recent studies indicated that the expression levels of Rho family members are also important in cancer. For example, the expression of RhoB was suppressed in invasive head and neck cancer (Adnane et al., 2002) , and the expression of RhoA and RhoC play an essential role in tumor invasion and metastasis (Yoshioka et al., 1999; Clark et al., 2000) .
Recent studies have suggested that RhoB can act as an activator of apoptosis in transformed cells (Fritz and Kaina, 2000; Liu, 2001) . The ability of RhoB to suppress the cell survival regulator AKT and NF-kB activity might contribute to the sensitivity of transformed cells to RhoB-dependent apoptosis (Fritz and Kaina, 2001a; Liu and Prendergast, 2000) . In addition, it was reported that RhoB might sensitize cells to anticancer agents including DNA-damaging agents, microtubule-destabilizing drugs and farnesyl transferase inhibitors. Loss or inactivation of RhoB may also contribute to the development of radioresistance or chemotherapeutic resistance in cancer (Prendergast, 2001) . In contrast, RhoA and RhoC play essential roles in transformation, metastasis and invasion of tumor cells (Yoshioka et al., 1999; Clark et al., 2000; van Golen et al., 2000; Kamai et al., 2001) .
Our data provide the first global view of the expression patterns of three Rho subfamily genes in transformed cells, and further support the hypothesis that RhoB has growth inhibitory function and might be a negative modifier in cancer (Du and Prendergast, 1999; Chen et al., 2000; Liu et al., 2001; Adnane et al., 2002) .
In summary, we have used global gene expression analysis to establish for the first time, a link between RhoB activity and HDAC inhibition, and have identified a DNA sequence within the RhoB promoter that mediated this regulation. The approach of mapping HDAC function to distinct DNA elements in regulatory regions of specific genes may have the potential of identifying specific target proteins that mediate promoter repression by HDAC inhibition. The induction of RhoB following HDAC inhibition offers a novel mechanism to explain some of the tumor suppression effects of HDAC inhibitors, enhancing the interest of developing HDAC inhibitors as anticancer drugs.
Materials and methods
Cell culture, transfection and reporter assay
The human nonsmall lung carcinoma cell line, H1299, and colon carcinoma cell line, HCT116, were cultured in RPMI 1640 (Life Technologies, Gaithersburg, MD, USA). HeLa cells were maintained in DMEM medium (Life Technologies). TPX (Novartis, Basal, Switzerland) was added directly to the cell medium at a final concentration of 30 nm. Transfections were performed using GenePORTER 2 (Gene Therapy Systems, San Diego, CA, USA) or FuGENE 6 (Roche, Indianapolis, IN, USA) transfection reagents according to the manufacturer's instructions. Luciferase and b-gal activity assays were performed according to the manufacturer's instructions (Promega, Madison, WI, USA). For the cotransfection experiment, luciferase activity was normalized to the pCMVb-gal activity. At least three independent experiments were performed for each assay.
Microarray analysis
Microarray analysis was performed essentially as described previously (Welsh, 2001) . Poly (A) þ RNA was prepared from H1299 cells treated with TPX or DMSO for 0, 6 and 24 h. Total RNA was prepared from 136 different cell lines. Labeled cDNA was prepared and hybridized to Affymetrix Hu6800 or U95a GeneChip oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). The arrays were scanned on an Affymetrix confocal scanner and analysed with GENECHIP 3.1 software (Affymetrix).
Northern and Western analysis
Total RNA was isolated from H1299 cells treated for 6 h with 30 nm TPX or DMSO using Trizol reagent (Life Technologies). The RNA samples were analysed by Northern blots using standard protocols. A full-length cDNA of p21 waf1 was used as probe. Specific probes for RhoA, RhoB and RhoC were amplified by RT-PCR and used for hybridizations. To ensure equal loading, the b-actin levels were used as a loading control. The primers used for probe amplification were the following:
For Western analysis, total protein was extracted from H1299 cells at 0, 6, 24 and 48 h following TPX treatment and hybridized with an antibody against RhoB (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Plasmid preparation
To identify the 5 0 -upstream region of the human RhoB gene, GenBank and Incyte LifeSeq databases were searched to identify RhoB cDNAs with the longest 5 0 -end extensions. The cDNA was subsequently mapped to the human genome. A 1 kb genomic region upstream of the cDNA start sites was selected as the putative promoter. A 0.97 kb human RhoB promoter fragment corresponding to a region from À253 to À1224, relative to the translation initiation site ( þ 1 ATG), was amplified (primer sequences underlined in Figure 4a ). The series of deletion fragments of the RhoB promoter was made by amplifying specific 5 0 -upstream sequences inserted into the pGL3 basic vector (Promega, Madison, WI, USA), which contains a luciferase reporter gene. These constructs were designated as pGL3RhoB1 (À1124/À253), pGL3RhoB2 (À821/À253), pGL3RhoB3 (À557/À253), pGL3RhoB4 (À497/À392) and pGLRhoB5-WT (À497/À392). The RhoB5 promoter fragments containing point mutations or insertions were used to generate pGL3RhoB5-M-CAAT pGL3RhoB5-M-TATA, pGL3RhoB5-M-CATA and pGL3RhoB5-M-Ins. pCMV-b-gal was purchased from Promega.
Gel shift assay
A 0.1 kb. double-stranded oligonucleotide probe selected from the human RhoB promoter, regions À497 to À392 (RhoB5), was labeled with [g-32 P]ATP and purified with MicroSpin TM G25 columns (Amersham PharmaciaBiotech). The gel shift assay was carried out using a Gel Shift Assay Kit (Promega, Madison, WI, USA). Nuclear extracts (10 mg) from H1299 cells were incubated with 5 ng of labeled probe in a 20 ml reaction volume for 20 min at room temperature. For competition test, 50-fold excess (250 ng) of unlabeled wild-type or mutant RhoB probes (as depicted in Figure 4d ) were added to each reaction. The reaction mixture was subjected to 6% polyacrylamide gel. Gels were dried and scanned with a Typhoon 9400 Variable Mode Imager (Molecular Dynamics Inc., Sunnyvale, CA, USA).
Chromatin immunoprecipitation
Chromatin immunoprecipitation analysis was conducted as described previously (Boyd et al., 1998; Moreno et al., 1999) . The chromatin was immunoprecipitated either with normal rabbit IgG, anti-acetyl-histone H3, anti-acetyl-histone H4, anti-HDAC1, anti-HDAC2 and anti-HDAC6 antibodies (Upstate Biotechnology, Lake Placid, NY, USA, and Santa Cruz Biotechnology, Santa Cruz, CA, USA), or without antibody. The supernatant fraction from the reaction lacking primary antibody was saved as the 'chromatin input'. DNAs were purified and used as the PCR templates to amplify the RhoB promoter regions from À823 to À536 and À557 to À412 relative to the translation initiation site. PCR products were separated on a 2% agarose gel, stained with ethidium bromide, and the images were recorded.
Cell transfection with antisense oligonucleotides
Oligonucleotides were synthesized as phosphorothioates (s) in chimeric form containing partly 2 0 -O-methoxyethyl-(MOE)-modified oligoribonucleotides. H1299 cells were transfected with HDAC1 antisense oligonucleotides NAS 6887, HDAC1 mismatch oligonucleotide NAS 7618, luciferase mismatch oligonucleotide NAS 5596 or mock transfected. The sequences of the oligonucleotides were: NAS 6887: 5 0 -GCTGTAsCsTsCsCsGsAsCsATGTT-3 0 , NAS 7618: 5 0 -GCTTTAsCsGsCsCsTsAsCsAGGTT-3 0 , NAS 5596: 5 0 -CCTTACsCsTsGsCsTsAsGsCTGGC-3 0 . Transfection was repeated twice on two consecutive days. Cells were harvested 72 h after the first transfection. RNA and protein were isolated using Trizol reagent (Life Technologies) according to the manufacturer's protocols.
Real time RT-PCR
Real time RT-PCR was performed using qPCR Core Kit (Eurogentec, Belgium) in an ABI PRISM 7700 Sequence Detector (Applied Biosystems, Forster City, CA, USA) following the manufacturer's instructions. HDAC1 forward primer (5 0 -GCGATGAGGACGAAGACGAC-3 0 ), HDAC1 reverse primer (5 0 -TCACAGGCAATTCGTTTGTCA-3 0 ) and HDAC1 TaqMan probe (5 0 -CTGACAAGCGCATCTC-GATCTGCTCC-3 0 ) containing 5 0 FAM fluorescent reporter and 3 0 TAMRA quencher dyes were used in the reaction at the final concentrations of 200 nm for primers and 100 nm for fluorescent probe. Relative measurement of the amplified product was performed using the comparative C T method as described in the manufacturer's manual (Applied Biosystems, ABI Prism 7700 sequence detection system, user bulletin 2).
